Role of Class IIa HDACs HDAC4 and HDAC7 in Pathogenic Th17 Cell Development and Colitis

IIa 类 HDAC HDAC4 和 HDAC7 在致病性 Th17 细胞发育和结肠炎中的作用

基本信息

  • 批准号:
    10557888
  • 负责人:
  • 金额:
    $ 42.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-02-01 至 2027-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Th17 cells play important roles in adaptive immunity and autoimmune diseases. In normal physiological conditions, Th17 cells produce IL-17A and IL-17F to protect the mucosa from bacterial and fungal infections. Dysregulation of Th17 cells, however, is responsible for inflammatory bowel diseases, multiple sclerosis and rheumatoid arthritis. Differentiation of Th17 cell lineage has been investigated intensively and has yielded significant results. The cooperation of key transcriptional factors such as Irf4, Batf, Stat3 together with lineage- specific regulator RorgT defines the transcriptional program and function of Th17 cells. These regulatory networks are induced by IL-6 and TGF-b1, and further IL-23 signaling pathways promote the development of pathogenic Th17 cells. To identify Th17-specific regulators, we recently conducted comprehensive ChIP-seq and RNA-seq studies of Th17 cells and discovered Class IIa Hdacs Hdac4 and Hdac7 as candidates that are transcriptionally regulated by Stat3 and BET proteins. We further found that Hdac4 and Hdac7 co-localize with distinct transcription factors JunB and Bhlhe40 on cis-regulatory regions of genes, to activate Th17 pathogenic genes (Il23r, Tgfb3, Il22, Csf2) and repress regulatory gene (Il10), respectively, during pathogenic Th17 cell differentiation (IL-6+IL-23+IL-1b). However, we still have limited mechanistic understanding how Hdac4 and Hdac7 function distinctly in pathogenic Th17 cell development. It is also unclear how Hdac4 and Hdac7 facilitate Th17 pathogenicity through the regulation of Th17 cell maintenance and/or plasticity in colitis. We therefore aim to delineate the role of Hdac4 and Hdac7 in Th17 cell-mediated inflammation, and establish the feasibility of pharmacological inhibition of Hdac4 and/or Hdac7 as a novel therapeutic strategy to treat Th17- related colitis.
项目摘要 Th 17细胞在获得性免疫和自身免疫性疾病中发挥重要作用。在正常生理 在某些条件下,Th 17细胞产生IL-17 A和IL-17 F以保护粘膜免受细菌和真菌感染。 然而,Th 17细胞的失调是炎症性肠病、多发性硬化症和 类风湿关节炎Th 17细胞谱系的分化已经被深入研究,并且已经产生了 显著的结果。关键转录因子如Irf 4、Batf、Stat 3与谱系- 特异性调节因子RogT定义了Th 17细胞的转录程序和功能。这些监管 网络是由IL-6和TGF-β 1诱导的,进一步的IL-23信号通路促进了 Th 17细胞为了确定Th 17特异性调节因子,我们最近进行了全面的ChIP-seq 和RNA-seq研究,发现IIa类Hdacs、Hdac 4和Hdac 7作为候选者, 由Stat 3和BET蛋白质转录调节。我们进一步发现,Hdac 4和Hdac 7共定位于 不同的转录因子JunB和Bhlhe 40在基因的顺式调节区,以激活Th 17致病性 IL 23 r、Tgfb 3、IL 22、Csf 2基因和IL 10基因在Th 17细胞中的表达 分化(IL-6+IL-23+IL-1b)。然而,我们仍然对Hdac 4和Hdac 4的机理了解有限。 Hdac 7在致病性Th 17细胞发育中具有独特的功能。目前还不清楚Hdac 4和Hdac 7是如何工作的。 通过调节结肠炎中的Th 17细胞维持和/或可塑性来促进Th 17致病性。我们 因此,目的是描述Hdac 4和Hdac 7在Th 17细胞介导的炎症中的作用,并建立 Hdac 4和/或Hdac 7的药理学抑制作为治疗Th 17- 与结肠炎有关

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kalung Cheung其他文献

Kalung Cheung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kalung Cheung', 18)}}的其他基金

Mechanism of Transcriptional Regulation of Th2 Cell Development
Th2细胞发育的转录调控机制
  • 批准号:
    10716014
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
Role of Class IIa HDACs HDAC4 and HDAC7 in Pathogenic Th17 Cell Development and Colitis
IIa 类 HDAC HDAC4 和 HDAC7 在致病性 Th17 细胞发育和结肠炎中的作用
  • 批准号:
    10711935
  • 财政年份:
    2022
  • 资助金额:
    $ 42.25万
  • 项目类别:
Role of Class IIa HDACs HDAC4 and HDAC7 in Pathogenic Th17 Cell Development and Colitis
IIa 类 HDAC HDAC4 和 HDAC7 在致病性 Th17 细胞发育和结肠炎中的作用
  • 批准号:
    10417716
  • 财政年份:
    2022
  • 资助金额:
    $ 42.25万
  • 项目类别:

相似海外基金

New roles of IFN-inducible OAS proteins in innate immune defense against bacterial infections
IFN诱导的OAS蛋白在针对细菌感染的先天免疫防御中的新作用
  • 批准号:
    10649771
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
Derivation and validation of a clinical prediction rule to identify febrile infants 61 to 90 days old at low and non-negligible risk of invasive bacterial infections
推导和验证临床预测规则,以识别 61 至 90 天大的发热婴儿,其侵袭性细菌感染的风险较低且不可忽略
  • 批准号:
    10574286
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
Structural and functional studies of YbtPQ for fighting bacterial infections
YbtPQ 对抗细菌感染的结构和功能研究
  • 批准号:
    10644889
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
A gut feeling: How can gastrointestinal bacterial infections alter female reproductive tract immunity and control of sexually transmitted infections
直觉:胃肠道细菌感染如何改变女性生殖道免疫力和性传播感染的控制
  • 批准号:
    MR/X031993/1
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Research Grant
Molecular probes to diagnose pathoadapatations in bacterial infections
诊断细菌感染病理适应的分子探针
  • 批准号:
    EP/X014479/1
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Research Grant
Using Small Area Variation Analysis to Investigate Sources of Practice Variation for Febrile Infants at Risk for Invasive Bacterial Infections
使用小面积变异分析来调查有侵袭性细菌感染风险的发热婴儿的实践变异来源
  • 批准号:
    10588846
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
  • 批准号:
    2306943
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Standard Grant
SimCell vaccines against Staphylococcus aureus bacterial infections
针对金黄色葡萄球菌细菌感染的 SimCell 疫苗
  • 批准号:
    10073241
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Grant for R&D
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
宿主定向 Orynotide 用于治疗耐多药革兰氏阴性细菌感染
  • 批准号:
    10674221
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了